Baillie Gifford & Co. Trims Stock Holdings in Edwards Lifesciences Corporation $EW

Baillie Gifford & Co. decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 572,247 shares of the medical research company’s stock after selling 10,351 shares during the quarter. Baillie Gifford & Co. owned approximately 0.10% of Edwards Lifesciences worth $44,504,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. UniSuper Management Pty Ltd increased its stake in shares of Edwards Lifesciences by 29.8% in the 3rd quarter. UniSuper Management Pty Ltd now owns 64,031 shares of the medical research company’s stock worth $4,980,000 after acquiring an additional 14,695 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares in the last quarter. Westfuller Advisors LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $79,000. Teacher Retirement System of Texas lifted its holdings in shares of Edwards Lifesciences by 88.1% during the third quarter. Teacher Retirement System of Texas now owns 377,974 shares of the medical research company’s stock valued at $29,395,000 after purchasing an additional 177,010 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Edwards Lifesciences by 13.0% in the 3rd quarter. Covestor Ltd now owns 1,627 shares of the medical research company’s stock worth $127,000 after purchasing an additional 187 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 11,386 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 57,824 shares of company stock valued at $4,863,323 in the last ninety days. 1.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Barclays reaffirmed an “overweight” rating and issued a $104.00 price target (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday. Finally, Wells Fargo & Company set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $96.82.

Edwards Lifesciences Price Performance

EW opened at $83.70 on Friday. The company’s 50-day simple moving average is $84.99 and its two-hundred day simple moving average is $80.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock has a market capitalization of $48.57 billion, a P/E ratio of 36.08, a P/E/G ratio of 3.19 and a beta of 0.95. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.